The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions
The treatment of HER2-positive cancers has changed significantly over the past ten years thanks to a significant number of promising new approaches that have been added to our arsenal in the fight against cancer, including monoclonal antibodies, inhibitors of tyrosine kinase, antibody–drug conjugate...
Main Authors: | Saleh Alrhmoun, Sergey Sennikov |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/24/6173 |
Similar Items
-
Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer
by: Katrin Almstedt, et al.
Published: (2023-02-01) -
The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
by: Zaid Sirhan, et al.
Published: (2022-07-01) -
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
by: Emanuela Ferraro, et al.
Published: (2021-08-01) -
HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
by: Mengyuan Cai, et al.
Published: (2023-07-01) -
From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer
by: Sun J, et al.
Published: (2022-07-01)